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Spironolactone prevents early renal injury in streptozotocin-
induced diabetic rats.
Background. Glomerular and tubulointerstitial injury leads
to chronic impairment of renal function, and thus, reversal of
the injury may improve renal function and survival. The present
study investigated whether and how mineralocorticoid recep-
tor antagonist spironolactone ameliorates early renal injury in
streptozotocin-induced diabetic rats.
Methods. Streptozotocin (65 mg/kg, single intraperitoneal
injection)- or vehicle-administered rats were used as diabetic
or control rats, respectively. The streptozotocin-administered
rats were treated with spironolactone (50 mg/kg/day sc) for 3
weeks. Among the 3 groups of rats, we compared renal fibro-
sis and renal hypertrophy, using picro-sirius red staining and
immunohistochemistry of ED-1 macrophage marker, plasmino-
gen activator inhibitor-1 (PAI-1), and transforming growth fac-
tor (TGF)-b1.
Results. Three weeks after administration of streptozo-
tocin, rats exhibited increased collagen deposition in glomeru-
lar, tubulointerstitial, and perivascular areas in the kidney,
which was completely attenuated by spironolactone treatment.
In rats given streptozotocin alone, there were increases in
ED-1–positive cell, PAI-1 expression, and TGF-b1 expression
in glomeruli and tubulointerstitiums, which were also sup-
pressed by spironolactone treatment. Maximal glomerular and
proximal tubular areas were not significantly different among
the 3 groups. Rats given streptozotocin alone revealed an in-
crease in proximal tubule wall-to-lumen ratio that was not in-
fluenced by treatment with spironolactone.
Conclusion. Streptozotocin-induced renal fibrosis, PAI-1
expression, TGF-b1 expression, and macrophage infiltration
occur via mineralocorticoid receptor, and spironolactone
ameliorates renal fibrosis presumably via the inhibition of
macrophage infiltration, PAI-1 expression, and TGF-b1 expres-
sion in streptozotocin-induced early diabetic injury.
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Diabetic nephropathy, a common complication in pa-
tients with either type 1 or type 2 diabetes mellitus,
has long been recognized to cause severe morbidity and
mortality. The renal structural alterations in susceptible
patients are characterized by the early appearance of
renal hypertrophy, the progressive accumulation of extra-
cellular matrix in the glomerulus and tubulointerstitium,
and consequently, glomerulosclerosis and tubulointersti-
tial fibrosis [1, 2]. Because glomerulosclerosis and tubu-
lointerstitial fibrosis cause renal dysfunction, reversal of
these changes may improve kidney function and survival.
Current therapeutic approaches to the reversal of pro-
gressive renal fibrosis in diabetes have been tried, but
have been relatively ineffective. On the other hand, a
mineralocorticoid receptor (MR) antagonist, spironolac-
tone, has been shown to prevent cardiovascular injury
[3–5], including diabetic renal injury [6]. Miric et al [6]
reported that 8 weeks after single streptozotocin (STZ)
administration, rats revealed increases in tubulointer-
stitial collagen volume fraction and kidney fibronectin
concentrations, which were reversed by treatment with
spironolactone for 4 weeks starting 4 weeks after STZ
administration. However, the mechanisms of action of
spironolactone are lacking.
Transforming growth factor (TGF)- b1 is known to
increase extracellular matrix synthesis, inhibit matrix
degradation, up-regulate adhesion molecules, and en-
hance chemoattraction [7, 8]. Increased TGF-b1 expres-
sion has been reported in experimental diabetic kidneys
and human diabetic patients [9–13], and TGF-b1 is an
important mediator in the diabetic renal injury [11–13].
The renoprotective effects of angiotensin I converting
enzyme (ACE) inhibition have been associated with re-
ductions in renal TGF-b1 expression in experimental di-
abetic nephropathy [14, 15]. However, it is not known
whether spironolactone affects TGF-b1 expression in
diabetic kidneys.
Plasminogen activator inhibitor-1 (PAI-1) is the ma-
jor physiologic inhibitor of plasminogen activators
(tissue-type plasminogen activator and urokinase-type
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plasminogen activator) in vivo [16], and has been impli-
cated in extracellular matrix accumulation by its effects
to inhibit matrix degradation [17, 18]. PAI-1 synthesis is
stimulated by TGF-b in normal and nephritic glomeruli
[19]. Angiotensin II and aldosterone stimulate expression
of PAI-1 in vitro in a number of cell types [20–23]. Inhibi-
tion of ACE prevented PAI-1 expression and perivascu-
lar fibrosis in a rat model with cardiovascular remodeling
induced by chronic inhibition of nitric oxide synthesis
[24]. Angiotensin II type 1 (AT1) receptor antagonist in-
hibited angiotensin II–induced PAI-1 expression in the
kidney [25]. However, it is not known whether spirono-
lactone can also act by these mechanisms in diabetic
nephropathy.
Experimental evidence has consistently demonstrated
an important role for macrophage in the development
of both glomerular and tubulointerstitial injury [26]. In-
filtrated macrophages release lysosomal enzymes, nitric
oxide, reactive oxygen intermediates, and TGF-b , which
have been reported to play an essential role in renal dam-
age [27–29]. However, while the presence of macrophage
has been noted in both the glomerulus and tubulointer-
stitium in human diabetic nephropathy [30], the mecha-
nisms which lead to their infiltration in diabetes are not
well understood. Recently, Kelly et al [31] used transgenic
diabetic (mRen-2)27 rats treated with STZ, and found
that the tubulointerstitial injury in diabetic nephropathy
is implicated in osteopontin expression and macrophage
accumulation, which were inhibited by treatment with a
blockade of the ACE. However, whether the renoprotec-
tive effects of spironolactone in diabetes may be related
to a reduction in macrophage infiltration has not yet been
explored.
Short term-exposure to moderate and severe hyper-
glycemia can cause the pathologic alteration in resistance
artery. Vranes et al [32] reported that vascular hypertro-
phy with collagen deposition was developed in superior
mesenteric artery from rats 3 weeks after single STZ in-
jection, and that this increase in blood vessel size is due
to an increase in the medial smooth muscle layer of the
vessel. This finding of vascular hypertrophy has been ex-
tended to include the renal vasculature [33]. Therefore,
the present study used a diabetic rat model 3 weeks after
single STZ administration, and examined whether and
how spironolactone suppresses renal injury, including re-
nal fibrosis and renal hypertrophy, using picro-sirius red
staining and immunohistochemistry of ED-1, PAI-1, and
TGF-b1.
METHODS
Animals
Experimental protocol for this study was approved by
Animal Ethics Committee of Jichi Medical School. Male
Sprague-Dawley rats (Japan SLC, Tokyo, Japan) weigh-
ing 180 to 200 g were divided into 3 groups (N = 6/group)
after measuring of body weight. Group 1 was given
65 mg/kg of STZ dissolved with 0.01 mol/L citrate buffer
(pH 4.5) (single intraperitoneal injection). Group 2 was
similarly given with an equal volume of citrate buffer.
Group 3 was subcutaneously treated with 50 mg/kg of
spironolactone (Pharmacia Corp., Peapack, NJ, USA)
dissolved in sesame oil for 21 days after STZ adminis-
tration. Groups 1 and 2 were also given an equal volume
of sesame oil in a similar manner.
Systolic blood pressures were measured by tail-cuff
plethysmography (Softran, Tokyo, Japan) before and
7, 14, and 20 days after vehicle or STZ administra-
tion. On study day 20, individual rats were placed in
metabolic cages to obtain 24-hour urine collections for
measurements of urine protein and albumin concentra-
tions. The urinary protein and albumin concentrations
were recorded with urinary creatinine concentration. On
study day 21, after determination of the body weight,
animals were decapitated. Collected trunk blood was
used for determination of plasma glucose, creatinine,
and aldosterone concentrations. Plasma aldosterone con-
centrations were measured by a radioimmunoassay kit
(Abbott Japan, Tokyo, Japan). The right kidney was then
removed and weighed. Upper third portion of the kidney
was transversely cut and was stocked in 3.7% formalde-
hyde solution. Specimens were embedded in paraffin and
cut into 5-lm thick slices transversely on a microtome
(Leica Corp., Nussloch, Germany).
Histology and immunohistochemistry
The kidney tissues were used for hematoxylin and
eosin, picro-sirius red staining, and immunohistochem-
istry of ED-1 macrophage marker, PAI-1 protein,
and TGF-b1 protein (avidin-biotin peroxidase complex
method; Vectastain Elite ABC kit, Vector Laboratory
Inc., Burlingame, CA, USA). For the 3 immunohisto-
chemistries, sections were incubated for 16 hours with
rabbit polyclonal antibodies against ED-1 (1:200; Serotec,
Oxford, UK), PAI-1 (1:200; American Diagnostica, Inc.,
Greenwich, CT, USA), and TGF-b1 (1:50; Santa Cruz,
CA, USA). Normal rabbit IgG was used as a negative
control in the staining. The number of ED-1–positive
cells in tubulointerstitium was determined according to
the method described by Mai et al [34]. A semiquantita-
tive score of PAI-1 immunostaining was used to evaluate
the degree of PAI-1 protein expression in glomerulus and
tubulointerstitium according to the method described by
Brown et al [35] and Zang et al [36], respectively. The
TGF-b1 immunostaining was also scored to analyze the
degree of TGF-b1 protein expression in glomerulus and
tubulointerstitium according to the methods described
by Shankland et al [37] and Toblli et al [38], respec-
tively. For the counting of ED-1–positive cells and the
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Table 1. Pathophysiologic parameters in control rats, rats treated with streptozotocin (STZ) alone, and rats treated with STZ plus spironolactone
(SPL)
P-Glu P-Cr P-Na P-K Rt-KW/ U-V U-Prot P-Aldo
Parameter mg/dL mg/dL mmol/L mmol/L BW g BW ×10−3 mL/day (mg/mg Cr) (ng/dL)
Control 122 ± 6 0.16 ± 0.02 127.3 ± 0.8 5.56 ± 0.25 76 ± 3 3.38 ± 0.08 11.3 ± 0.9 1.29 ± 0.31 27.7 ± 6.4
STZ 488 ± 52b 0.14 ± 0.02 125.3 ± 3.2 5.67 ± 0.18 22 ± 11b 5.16 ± 0.14b 18.2 ± 2.4a 1.05 ± 0.36 24.8 ± 7.4
STZ+SPL 587 ± 43b 0.17 ± 0.02 124.0 ± 2.4 6.00 ± 0.38 –16 ± 11b,d 5.12 ± 0.17b 24.9 ± 1.5b,c 0.88 ± 0.16 90.0 ± 15.3b,d
Abbreviations are: P-Glu, plasma glucose concentration; P-Cr, plasma creatinine; P-Na, plasma sodium; P-K, plasma potassium; BW, change in body weight
(+BW and −BW represent gain and loss of body weight, respectively); Rt-KW/BW, ratio of right kidney weight to body weight; U-V, urinary volume; U-Prot,
urinary protein; P-Aldo, plasma aldosterone concentration. Values are mean ± SEM. The number of animals in each group was 6.
aP < 0.05; bP < 0.01 vs. control by ANOVA; cP < 0.05; dP < 0.01 vs. STZ by ANOVA.
scoring of PAI-1 and TGF-b1 immunostaining, 100
glomeruli (magnification, ×400) and 40 tubulointerstitial
areas of the stained tissue within a given field without
vessels or glomeruli (magnification, ×200) were selected
at random and were determined by computerized image
analysis system (Mac Scope, Fukui, Japan).
Morphometric analysis
Sections stained with picro-sirius red were analyzed
for collagen volume fraction in glomerular, tubuloint-
erstitial, and perivascular areas with an image analysis
system. For analyses of the glomerular and tubu-
lointerstitial collagen volume fractions, 20 glomerular
capsules and 20 fields without vessels or glomeruli were
randomly selected from each kidney section, respectively.
The glomerular and tubulointerstitial collagen volume
fractions were then calculated as percentage of stained
area within traced glomerular capsules and as percent-
age of total area within a field, respectively. Perivascular
collagen volume fraction was measured as an area for a
sample of the vessels in the section in order to correct
differences in vessel size. Data were expressed as an area
of perivascular collagen per media area.
Glomerular and tubular cross-sectional areas were de-
cided in sections stained with hematoxylin and eosin.
Thirty glomerular Bowman’s capsules including tuft and
outer surfaces of proximal tubules including brush bor-
der were traced, and the maximum cross-sectional areas
were determined. Then, the ratio of the cross-sectional
area of the outer surface of the proximal tubule to the
cross-sectional area of the inner surface of the tubule was
determined as a parameter of tubular hypertrophy.
Statistics
Results are presented as mean ± SEM, and data were
analyzed by Student unpaired t test or analysis of variance
(ANOVA) for repeated measures, following by post-hoc
analysis with Fisher test, where appropriate. P < 0.05 was
considered statistically significant.
RESULTS
Table 1 shows pathophysiologic parameters in the 3
groups of rats. Plasma glucose levels in rats given STZ
Table 2. Systolic blood pressure in control rats, rats treated with
streptozotocin (STZ) alone, and rats treated with STZ plus
spironolactone (SPL) on study day 0, 7, 14, and 20
Day 0 7 14 20
Control 120 ± 3 118 ± 1 117 ± 2 120 ± 3
STZ 116 ± 2 119 ± 3 119 ± 3 126 ± 1a
STZ + SPL 119 ± 2 117 ± 2.4 123 ± 2 118 ± 4
Values (mm Hg) are mean ± SEM; the number of animals in each group was
6.
aP < 0.01 vs. systolic blood pressure in rats given STZ alone on day 0 by
ANOVA.
alone (488 ± 52 mg/dL) were markedly increased as com-
pared with control rats (122 ± 6 mg/dL). In rats given
STZ plus spironolactone, they were 587 ± 43 mg/dL, val-
ues that were not significantly different from those in rats
given STZ alone. Plasma creatinine levels were not sig-
nificantly different among the 3 groups. Plasma sodium
concentrations were without significant changes among
the 3 groups. Plasma potassium concentrations in the
rats given STZ plus spironolactone (6.00 ± 0.38 mmol/L)
were slightly greater than those in control rats (5.56 ±
0.25 mmol/L) and in the rats given STZ alone (5.67 ±
0.19 mmol/L), but did not arrive at statistical significance.
Table 2 shows systolic blood pressure in the 3 groups of
rats for up to 20 days after the treatment with vehicle or
STZ. Systolic blood pressure on study day 0, 7, 14, or 20
was not significantly different among the 3 groups. On
the other hand, in rats given STZ alone, systolic blood
pressure on study day 20 (126 ± 1 mm Hg) was slightly
but significantly greater than that on study day 0 (116 ±
2 mm Hg). Body weight increase in rats given STZ alone
(22 ± 11 g) was significantly smaller than in control rats
(76 ± 3 g). In sharp contrast, body weight decrease (16 ±
11 g) was observed in rats given STZ plus spironolactone.
In rats given STZ alone, kidney weight as a parameter of
kidney hypertrophy was 5.16 ± 0.14 mg/g body weight,
the value that was significantly greater than in control rats
(3.38 ± 0.08 mg/g body weight). Treatment with spirono-
lactone (5.12 ± 0.17 mg/g body weight) had no effect on
STZ-induced increase in kidney weight. Urine volume in
rats given STZ alone (18.2 ± 2.4 mL/day) was significantly
greater than in control rats (11.3 ± 0.9 mL/day), whereas
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in rats given STZ plus spironolactone (24.9 ± 1.5 mL/day)
it was significantly greater than in rats given STZ alone
and control rats. Urinary protein excretion was without
significant changes among the 3 groups. Urinary albumin
concentrations in 2 rats given STZ alone were 0.815 and
0.787 mg/mg creatinine, but urine albumin was not de-
tected in the remaining 4 rats given STZ alone. On the
other hand, urine albumin was not detected in control
rats or rats given STZ plus spironolactone. Plasma aldos-
terone concentrations in rats given STZ alone (24.8 ±
7.4 ng/dL) were not significantly different from those in
control rats (27.7 ± 6.4 ng/dL), whereas in rats given
STZ plus spironolactone, they were markedly increased
(90.0 ± 15.3 ng/dL).
Figure 1 shows histologic findings by picro-sirius red
staining of transverse kidney sections in control rats
(Fig. 1A), rats given STZ alone (Fig. 1B), and rats given
STZ plus spironolactone (Fig. 1C). In rats given STZ
alone, periarteriolar fibrosis, tubulointerstitial fibrosis,
and intraglomerular fibrosis were found. In marked con-
trast, in rats given STZ plus spironolactone, the STZ-
induced periarteriolar fibrosis, tubulointerstitial fibrosis,
and intraglomerular fibrosis were normalized. Figure 2
summarizes the alteration of collagen volume fraction
in glomerular area (Fig. 2A), tubulointerstitial area
(Fig. 2B), and perivascular area (Fig. 2C) of the right
kidney in the 3 groups of rats, respectively. Glomerular
collagen volume fraction in rats given STZ alone (4.43 ±
1.76%) was markedly increased as compared with con-
trol rats (0.71 ± 0.24%). In rats given STZ plus spirono-
lactone, glomerular collagen volume fraction was 0.79 ±
0.12%, a value that was significantly smaller than in
rats given STZ alone, but was not significantly differ-
ent from that in control rats. Alteration of tubulointer-
stitial collagen volume fraction was markedly similar to
that of the glomerular collagen volume fraction (Fig. 2B;
control rats: 0.15 ± 0.02%; rats given STZ alone: 0.40 ±
0.07%; rats given STZ plus spironolactone: 0.18 ±
0.01%). Perivascular collagen volume fraction in rats
given STZ alone was 1.48 ± 0.19%, significantly greater
than in control rats (0.97 ± 0.07%). In rats given STZ
plus spironolactone, perivascular collagen volume frac-
tion was reduced to the control level by the treatment
with spironolactone (0.99 ± 0.11%).
We next examined the number of ED-1–staining cells,
and PAI-1 and TGF-b1 immunostaining in the 3 groups
of rat kidneys. Figure 3A to C shows histologic findings
of the ED-1–positive cells as a marker of macrophage
in kidneys from control rats, rats given STZ alone, and
rats given STZ plus spironolactone, respectively. In con-
trol kidney sections, very few macrophages were de-
tected in glomeruli. In rats given STZ alone, macrophage
infiltration was facilitated in glomeruli and tubuloin-
terstitium. Treatment with spironolactone ameliorated
the STZ-induced macrophage infiltration in both areas.
A
B
C
Fig. 1. Histologic findings by picro-sirius red staining of transverse kid-
ney sections in the control rats (A), rats given streptozotocin (STZ)
alone (B), and rats given STZ plus spironolactone (SPL) (C). Magnifi-
cation, ×200.
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Fig. 2. Collagen volume fraction determined by picro-sirius red stain-
ing in the three groups of rat kidneys. (A) glomerulus; (B) tubuloint-
erstitium; (C) perivascular area. Values are mean ± SEM. +P < 0.05;
++P < 0.01vs. control; ∗P < 0.05; ∗∗P < 0.01 vs. STZ alone by ANOVA.
Figure 4A and B shows quantitation of macrophage num-
ber in glomeruli and tubulointerstitium from 3 groups
of rat kidneys, respectively. In glomeruli of rats given
STZ alone, the number of ED-1–positive cells was 3.57 ±
0.13/glomerulus, significantly greater than in control rats
(1.21 ± 0.15/glomerulus). Treatment with spironolactone
completely suppressed the STZ-induced increase in the
number of ED-1–positive cells (1.67 ± 0.16/glomerulus).
In tubulointerstitium of rats given STZ alone, the num-
ber of ED-1–positive cells was 1.42 ± 0.13/mm2, signif-
icantly greater than in control rats (0.74 ± 0.13/mm2).
On the other hand, in tubulointerstitium of rats given
STZ plus spironolactone, the number of ED-1–positive
cells was 0.64 ± 0.10/mm2, a value that was significantly
smaller than that in rats given STZ alone, but was not
significantly different from that in control rats. Figure 3D
to F shows PAI-1 immunostaining in kidneys from con-
trol rats, rats given STZ alone, and rats given STZ plus
spironolactone, respectively. In control kidney sections,
PAI-1 immunostaining was detected in some tubulointer-
stitiums, whereas very few PAI-1 immunostainings were
observed in glomeruli. In sharp contrast, in rats given STZ
alone, PAI-1 immunostaining was increased diffusely in
the tubulointerstitium and glomerulus. Treatment with
spironolactone markedly suppressed the STZ-induced
PAI-1 immunostaining in both areas; the suppression
of PAI-1 immunostaining was especially more promi-
nent in the glomerulus than in the tubulointerstitium.
Figure 4C and D shows the alteration of the score of
PAI-1 immunostaining in glomeruli and tubulointersti-
tium of each group, respectively. In glomeruli, the score
in rats given STZ alone was increased to 1.90 ± 0.14 as
compared with the control rats (0.72 ± 0.03). Spironolac-
tone completely suppressed the STZ-induced increase in
the score (0.96 ± 0.16). In tubulointerstitium of rats given
STZ alone, the PAI-1 immunostainning area was signif-
icantly increased to 20.47 ± 1.79 (%/mm2) as compared
with that in control rats (5.93 ± 0.34%/mm2). The PAI-1
immunostaining area in rats given STZ plus spirono-
lactone (10.83 ± 1.46%/mm2) was significantly smaller
than that in rats given STZ alone, but was still signifi-
cantly greater than that in the control rats. Figure 3G to
I shows TGF-b1 immunostaining in kidneys from con-
trol rats, rats given STZ alone, and rats given STZ plus
spironolactone, respectively. In control kidney sections,
TGF-b1 immunostaining was detected in some glomeruli
and tubulointerstitiums. The rats given STZ alone exhib-
ited greater TGF-b1 immunostaining in glomeruli and
tubulointerstitiums, whereas treatment with STZ plus
spironolactone showed smaller TGF-b1 immunostaining
areas in glomeruli and tubulointerstitiums. Figure 4E and
F shows alteration of the score of TGF-b1 immunostain-
ing in glomeruli and tubulointerstitium, respectively. In
glomeruli, the score in rats given STZ alone was signifi-
cantly increased to 1.42 ± 0.13 as compared with control
rats (0.74 ± 0.13). Spironolactone completely suppressed
the STZ-induced increase in the score (0.64 ± 0.10). In
tubulointerstitium, the score of TGF-b1 immunostaining
in rats given STZ alone was 1.63 ± 0.17, a value that was
significantly greater than in control rats (0.60 ± 0.08). In
rats given STZ plus spironolactone, the score was 0.97 ±
0.02, a value that was significantly smaller than in rats
given STZ alone, but was still significantly greater than
in control rats.
To clarify the cause of increase in kidney weight in
rats given STZ alone and in rats given STZ plus spirono-
lactone, we finally determined the maximal glomerular
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Fig. 3. Immunohistochemical findings by anti-ED-1 antibody (A-C), anti-plasminogen activator inhibitor-1 (PAI-1) antibody (D-F), and anti-
transforming growth factor-b1 (TGF-b1) antibody (G-I) in the three groups of rat kidneys. (A), (D), and (G), control rats; (B), (E), and (H), rats
given STZ alone; (C), (F), and (I), rats given STZ plus spironolactone. Magnification, ×400.
Bowman’s capsular area and proximal tubular cross-
sectional area, and the proximal tubule wall-to-lumen
ratio, as shown in Figure 5. There were no significant
changes of maximal glomerular Bowman’s capsular area
or proximal tubular cross-sectional area among the 3
groups. In marked contrast, the proximal tubule wall-to-
lumen ratio as a parameter of tubular hypertrophy in rats
given STZ alone was increased to 23.8 ± 0.2 as compared
with the control rats (12.6 ± 0.9). Spironolactone had no
effect on STZ-induced increase in the ratio (24.7 ± 3.5).
DISCUSSION
Eight weeks after single STZ injection, rats have been
reported to exhibit hyperglycemia and renal fibrosis [6].
In this model, spironolactone had an antifibrotic effect
on the kidney [6], a finding attributed to blockade of tis-
sue MRs. The goal of the present study was to determine
the mechanisms by which hyperglycemic state induces
renal injury via MRs, especially the involvement of
macrophage infiltration, PAI-1 expression, and TGF-b1
expression in the detrimental effects of the exposure to
hyperglycemia on kidney. To do this, we used the MR an-
tagonist spironolactone to examine the effects of the drug
on hyperglycemia-induced hypertension, renal fibrosis,
tubular hypertrophy, macrophage infiltration, PAI-1 ex-
pression, and TGF-b1 expression.
We observed that 3 weeks after the single STZ in-
jection, there were significant increases in rats in blood
glucose levels, kidney weight, as well as intraglomerular
fibrosis, tubulointerstitial fibrosis, and periarteriolar fi-
brosis, and tubular hypertrophy. In rats given STZ alone,
there were no significant increases in plasma creatinine
levels or urinary protein excretion when compared with
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Fig. 4. The number of ED-1–positive cells in glomerulus (A) and tubu-
lointerstitium (B), the score of PAI-1 immunostaining area in glomeru-
lus (C), the PAI-1 immunostaining area in tubulointerstitium (D), and
the score of TGF-b1 immunostaining area in glomeruli (E) and tubu-
lointerstitium (F) in the three groups of rat kidneys. Values are mean ±
SEM. +P < 0.05; ++P < 0.01 vs. control; ∗P < 0.05; ∗∗P < 0.01 vs. STZ
alone by ANOVA, #P < 0.05 vs. STZ alone by unpaired Student t test.
the control rats. In 2 of 6 rats given STZ alone, urine al-
bumin was detected. Therefore, 3 weeks after the single
STZ injection the rats exhibited early stage of diabetic
nephropathy [39, 40]. Interestingly, we also found that
PAI-1 protein expression, TGF-b1 protein expression,
and macrophage infiltration were markedly increased in
the kidney from rats given STZ alone. Furthermore, we
observed that treatment with spironolactone completely
inhibited the STZ-induced increase in intraglomeru-
lar fibrosis, tubulointerstitial fibrosis, and periarteriolar
fibrosis. We also demonstrated that spironolactone had
no effects on STZ-induced increases in kidney weight
or tubular hypertrophy. These findings indicate that
the STZ-induced tubulointerstitial fibrosis, intraglomeru-
lar fibrosis, and periarteriolar fibrosis occur via MRs,
whereas the STZ-induced increase in kidney weight or
tubular hypertrophy does not. The present study also ob-
served that the STZ-induced PAI-1 protein expression,
TGF-b1 protein expression, and macrophage infiltration
in the glomeruli and tubulointerstitium were inhibited by
treatment with spironolactone, consistent with the notion
that the STZ-induced PAI-1 protein expression, TGF-b1
protein expression, and macrophage infiltration in the
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Fig. 5. The maximal glomerular Bowman’s capsule area (A), maximal
proximal tubular area (B), and proximal tubule wall-to-lumen ratio (C)
in the three groups of rat kidneys. Values are mean ± SEM. +P < 0.01
vs. control by ANOVA.
glomeruli and tubulointerstitium occur also via MRs. This
is the first demonstration of a link between the MRs and
PAI-1 expression, TGF-b1 expression, and macrophage
infiltration in diabetic nephropathy.
The mechanisms whereby STZ-induced proximal
tubule hypertrophy occurs via spironolactone-insensitive
processes are not clear at present. Rats given STZ
alone and rats given STZ plus spironolactone exhibited
elevated blood glucose levels with similar magnitude.
Therefore, it is possible that the elevated blood glucose
levels may contribute to the spironolactone-insensitive
tubular hypertrophy. This possibility is supported by the
report of Ziyadeh et al [41], who showed that in prox-
imal tubule cells in culture, elevated glucose concen-
trations induced cell hypertrophy. In glomerulus and
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tubulointerstitium of rats given STZ alone, PAI-1 expres-
sion, TGF-b1 expression, and macrophage infiltration
were increased. Spironolactone partially inhibited the
STZ-induced PAI-1 expression and TGF-b1 expression
in tubulointerstitium, whereas it completely inhibited the
STZ-induced macrophage infiltration in glomerulus and
tubulointerstitium, as well as the STZ-induced PAI-1 ex-
pression and TGF-b1 expression in glomerulus. These
findings suggest that, in the kidneys of rats given STZ with
and without spironolactone, the PAI-1 expression may be
parallel with the TGF-b1 expression, and that the effect
of spironolactone on STZ-induced renal PAI-1 expres-
sion and TGF-b1 expression differs between glomerulus
and tubulointerstitium. In other words, in tubulointer-
stitium, the STZ-induced PAI-1 and TGF-b1 expression
is mediated by spironolactone-sensitive and -insensitive
processes, whereas, in glomerulus, the STZ-induced PAI-
1 and TGF-b1 expression is exclusively mediated by
spironolactone-sensitive MRs. Further studies will be re-
quired to clarify the spironolactone-insensitive processes.
Recent studies indicate that aldosterone contributes to
renal injury in animal models of hypertension [3, 42, 43].
MR antagonism with spironolactone decreases glomeru-
lar damage and arteriopathy in the stroke-prone sponta-
neously hypertensive rats [3] and in the 5/6 nephrectomy
model of hypertension [42]. In spontaneously hyperten-
sive rats, aldosterone induces and spironolactone attenu-
ates renal injury in the absence of blood pressure effects
[3, 43], suggesting that aldosterone exerts direct nephro-
toxic effects. In the present study, we indeed observed
that rats given STZ alone exhibited renal fibrosis, which
was completely inhibited by treatment with spironolac-
tone. In rats given STZ alone, on study day 20, there was
a slight elevation of systolic blood pressure compared
with that on study day 0, although in control rats or rats
given STZ plus spironolactone, on study day 20 there was
no change in the blood pressure compared with that on
study 0. On the other hand, the blood pressure on study
day 0, 7, 14, or 20 was not significantly different among
the 3 groups of rats. Therefore, the effect of spirono-
lactone on STZ-induced renal fibrosis should possibly
occur independently of blood pressure effect, although
we cannot completely exclude the blood pressure effect.
More importantly, this study is the first to demonstrate
that aldosterone contributes to hyperglycemia-induced
increase in PAI-1 expression, TGF-b1 expression, and
macrophage infiltration in the kidney via MRs. Alterna-
tively, the aldosterone-induced renal injury may occur
via endothelin (ET)-1 activation, because in aldosterone-
infused rats, cardiac and aortic interstitial and perivascu-
lar collagen depositions were increased, and all of them
were prevented by BMS 182874, the selective ET-1 A
receptor antagonist [44]. Furthermore, Pu et al [45] re-
ported that aldosterone infusion in rats raised blood
pressure, increased plasma ET-1 levels, induced oxida-
tive stress, and collagen and fibronectin deposition in
the media of small mesenteric arteries and increased
abundance of intercellular adhesion molecule-1 in the
vascular wall, and that these changes were prevented by
treatment with spironolactone and BMS 182874. There-
fore, the aldosterone-induced effects may be mediated by
ET-1–sensitive processes that involve oxidative stress.
Numerous other studies have demonstrated a renopro-
tective effect of ACE inhibitors and AT1 receptor an-
tagonists in both hypertensive and normotensive settings
[46–48]. In addition, ACE inhibitors and AT1 recep-
tor antagonists have previously been shown to suppress
PAI-1 expression in a balloon-injured aorta model and
in radiation nephropathy [49–51]. Diabetic rats given
STZ showed elevated expression of monocyte chemoat-
tractant protein-1 (MCP-1), a key macrophage chemoat-
tractant and activator, macrophage number in glomeruli,
and proteinuria, which were suppressed by the treat-
ment with the ACE inhibitor enalapril and the AT1 re-
ceptor antagonist candesartan [52]. Furthermore, Kelly
et al [31] reported that ACE inhibition with perindo-
pril was associated with attenuation of osteopontin ex-
pression, macrophage infiltration, and tubulointerstitial
injury in transgenic diabetic rats treated with STZ. How-
ever, they have not yet addressed the inhibitory effects of
the MR antagonism with spironolactone on PAI-1 expres-
sion, TGF-b1 expression, and macrophage infiltration in
their animal models.
The mechanism by which aldosterone contributes to
the development of renal fibrosis in animal models of di-
abetes is not known at present; however, several lines
of evidence support the hypothesis that aldosterone
causes thrombosis and accumulation of extracellular ma-
trix, leading to fibrosis by increasing PAI-1 expression.
First, aldosterone interacts with angiotensin II to increase
PAI-1 expression in both vascular smooth muscle cells
and endothelial cells [23]. Second, serum aldosterone
concentrations correlate with PAI-1 antigen concentra-
tions in humans [23, 53], supporting a role of aldosterone
in vivo in regulation of PAI-1 as well. In support of
a role for PAI-1 in the regulation of fibrosis, Eitzman
et al [17] have reported that bleomycin-induced pul-
monary fibrosis is increased in transgenic mice over-
expressing PAI-1 and decreased in PAI-1 knockout mice
relative to control rats. Alternatively, aldosterone may in-
duce an increase in TGF-b1 expression, and consequently
increase extracellular matrix synthesis, inhibit matrix
degradation, up-regulate adhesion molecules, enhance
chemoattraction [7, 8], and increase PAI-1 expression
[19], leading to renal fibrosis. It is also possible that
aldosterone may increase MCP-1 expression, which is
therefore involved in progressive glomerular and tubu-
lointerstitial damage via macrophage recruitment and ac-
tivation. This is supported by the recent report of Blasi
et al [54], who showed that aldosterone/salt-induced renal
injury and fibrosis were associated with macrophage infil-
tration and up-regulation of cytokines, including MCP-1,
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and that all of them were attenuated by treatment with
eplerenone (a selective MR antagonist). Future stud-
ies will be required to clarify how PAI-1, TGF-b1, and
macrophage infiltration are implicated in diabetic kidney
fibrosis.
In the present study, we found that plasma aldosterone
concentrations in rats given STZ alone were similar to
those in the control rats, whereas, in rats given STZ plus
spironolactone, they were significantly greater than those
in rats given STZ alone and control rats. This finding is
in good agreement with those of Miric et al [6]. They
reported that 8 weeks after single STZ administration,
plasma aldosterone concentrations in rats were not differ-
ent from those in control rats, whereas in rats given STZ
plus spironolactone, plasma aldosterone concentrations
were markedly elevated, despite the fact that spironolac-
tone reversed the STZ-induced increase in tubulointer-
stitial collagen volume faction and fibronectin concentra-
tion [6]. Similarly, Brown et al [35] reported that spirono-
lactone suppressed radiation-induced nephrosclerosis via
inhibition of PAI-1 expression, in spite of normal serum
aldosterone levels. Taken together with the present find-
ing that spironolactone inhibited the development of fi-
brosis, PAI-1 protein expression, TGF-b1 protein expres-
sion, and macrophage infiltration in the early stage of
diabetic kidney, this suggests that circulating concentra-
tions of aldosterone do not reflect local tissue levels of
aldosterone. In support of this hypothesis, extra-adrenal
synthesis of aldosterone has been documented in vas-
cular smooth muscle cells [55] and heart [56]. For these
reasons, the demonstration that aldosterone antagonism
attenuates the development of fibrosis, PAI-1 protein ex-
pression, TGF-b1 protein expression, and macrophage
infiltration in the early stage of diabetic nephropathy may
provide the better evidence for a role of endogenous al-
dosterone in this model of diabetic nephropathy. Whether
aldosterone is actually produced in the diabetic kidney
will have to wait further investigation.
Spironolactone is known to cause hyperkalemia. How-
ever, in rats given STZ plus spironolactone (50 mg/kg/day
sc) for 21 days, plasma potassium concentrations were
not significantly elevated compared with those in con-
trol rats or rats given STZ alone (see Table 1). This may
result from the normal renal function in rats given STZ
plus spironolactone. Similarly, Miric et al [6] reported that
there were no significant differences of plasma potassium
concentrations among rats 8 weeks after single STZ ad-
ministration, rats given spironolactone at the same doses
for 4 weeks starting 4 weeks after STZ administration,
control rats, and control rats given spironolactone alone
for 4 weeks. The result that plasma potassium concen-
trations did not significantly differ among the 3 groups
of rats excludes the possibility that plasma potassium is
implicated in early diabetic renal injury.
In rats given STZ alone, the body weight gain was less
than that in the control rats. On the other hand, rats given
STZ plus spironolactone exhibited a body weight loss.
The reasons for this are not known at present. The in-
crease in urine volume was greater in rats given STZ plus
spironolactone than in given STZ alone, whereas the in-
crease in blood glucose levels was not significantly differ-
ent between the 2 groups of rats. Thus, the body weight
loss in rats given STZ plus spironolactone may be due to
a greater increase of urine output, although we did not
measure water intake or food intake in the rats.
CONCLUSION
STZ-induced renal fibrosis, PAI-1 expression, TGF-b1
expression, and macrophage infiltration occur via MRs,
and spironolactone ameliorates renal fibrosis presumably
via the inhibition of PAI-1 expression, TGF-b1 expres-
sion, and macrophage infiltration in STZ-induced early
diabetic kidney. Spironolactone is generally used as a
diuretic to reduce the extracellular fluid volume with-
out causing potassium depletion or hypokalemia in ad-
vanced renal injury in diabetes. However, the present
study strongly indicates that inhibition of the MRs by
spironolactone might provide a novel therapeutic strat-
egy in early diabetic injury as an antifibrotic agent as well.
ACKNOWLEDGMENT
We thank Pharmacia for financial support. A portion of this work was
presented at the 75th American Heart Association Scientific Sessions
in Chicago. This work was partly supported by a grant from the Grants-
in-Aid for Scientific Research from the Ministry of Education, Science,
Sports, and Culture in Japan.
Reprint requests to Genro Fujisawa, M.D., Division of Endocrinology
& Metabolism, Jichi Medical School, Minamikawachi, Tochigi, 329–0498
Japan.
E-mail: genrfjs@attglobal.net
REFERENCES
1. MAUER SM, STEFFES MW, ELLIS EN, et al: Stractural-functional rela-
tionships in diabetic nephropathy. J Clin Invest 74:1143–1155, 1984
2. ZIYADEH FN, GOLDFARB S: The renal tubulo-interstitium in diabetes
mellitus. Kidney Int 39:464–475, 1991
3. ROCHA R, CHANDER PN, KHANNA K, et al: Mineralocorticoid block-
ade reduces vascular injury in stroke-prone hypertensive rats. Hy-
pertension 31:451–458, 1998
4. BRILLA CG, MATSUBARA LS, WEBER KT: Anti-aldosterone treat-
ment and the prevention of myocardial fibrosis in primary and sec-
ondary hyperaldosteronism. J Mol Cell Cardiol 25:563–575, 1993
5. FUJISAWA G, OKADA K, MUTO S, et al: Na/H exchange isoform 1 is
involved in mineralocorticoid induced cardiac injury. Hypertension
41:493–498, 2003
6. MIRIC G, DALLEMAGNE C, ENDRE Z, et al: Reversal of cardiac and
renal fibrosis by pirfenidine and spironolactone in streptozotocin-
diabetic rats. Br J Pharmacol 133:687–694, 2001
7. SHARMA K, ZIYADEH FN: Renal hypertrophy is associated with up-
regulation of TGF-b1 gene expression in diabetic BB rat and NOD
mouse. Am J Physiol 267:F1094–F1098, 1994
8. SHARMA K, JIN Y, GUO J, et al: Neutralization of TGF-b by anti-
TGF-b antibody attenuates kidney hypertrophy and the enhanced
extracellular matrix gene expression in STZ-induced diabetic mice.
Diabetes 45:522–530, 1996
9. SHANKLAND SJ, SCHOLEY JW, LY H, et al: Expression of transform-
ing growth factor-b1 during diabetic renal hypertrophy. Kidney Int
46:430–442, 1994
1502 Fujisawa et al: Spironolactone effect on early diabetic renal injury
10. PFEIFFER A, MIDDLEBERG-BISPRING K, DREWES C, et al: Elevated
plasma levels of transforming growth factor-b1 in NIDDM. Diabetes
Care 19:1113–1117, 1996
11. PARK I-S, KIYOMOTO H, ABBOUD SL, et al: Expression of transform-
ing growth factor-b and Type IV collagen in early streptozotocin-
induced diabetes. Diabetes 46:473–480, 1997
12. NAKAMURA T, FUKUI M, EBIHARA I, et al: mRNA expression of
growth factors in glomeruli from diabetic rats. Diabetes 42:450–456,
1993
13. YOUNG BA, JOHNSON RJ, ALPERS CE, et al: Cellular events in the
evolution of experimental diabetic nephropathy. Kidney Int 47:935–
944, 1995
14. GILBERT RE, COX A, WU LL, et al: Expression of transforming
growth factor-b1 and type IV collagen in the renal tubulointersti-
tium in experimental diabetes. Diabetes 47:414–422, 1998
15. HILL C, LOGAN A, SMITH C, et al: Angiotensin converting enzyme
inhibitor suppresses glomerular transforming growth factor beta
receptor expression in experimental diabetes in rats. Diabetologia
44:495–500, 2001
16. SAKSELA O, RIFKIN DB: Cell-associated plasminogen activation:
Regulation and physiologic functions. Annu Rev Cell Biol 4:93–126,
1988
17. EITZMAN DT, MCCOY RD, ZHENG X, et al: Bleomycin-induced pul-
monary fibrosis in transgenic mice that either lack or overexpress
the murine plasminogen activator inhibitor-1 gene. J Clin Invest
97:232–237, 1996
18. EDDY SS: Plasminogen activator inhibitor-1 and the kidney. Am J
Physiol Renal Physiol 283:F209–F220, 2002
19. TOMOOKA S, BORDER WA, MARSHALL BC, et al: Glomerular matrix
accumulation is linked to inhibition of the plasmin protease system.
Kidney Int 42:1462–1469, 1992
20. VAUGHAN DE, LAZOS SA, TONG K: Angiotensin II regulates the ex-
pression of plasminogen activator inhibitor-1 in cultured endothelial
cells. J Clin Invest 95:995–1001, 1995
21. VAN LEEUWEN RT, KOL A, ANDREOTTI F, et al: Angiotensin II in-
creases plasminogen activator inhibitor type 1 and tissue-type plas-
minogen activator messenger RNA in cultured rat aortic smooth
muscle cells. Circulation 90:362–368, 1994
22. KAGAMI S, KUHARA T, OKADA K, et al: Dual effects of angiotensin II
on the plasminogen/plasmin system in rat mesangial cells. Kidney
Int 51:664–671, 1997
23. BROWN NJ, KIN KS, CHEN YQ, et al: Synergistic effect of adrenal
steroids and angiotensin II on plasminogen activator inhibitor-1
production. J Clin Endocrinol Metab 85:336–344, 2000
24. KATOH M, EGASHIRA K, MITSUI T, et al: Angiotensin-converting
enzyme inhibitor prevents plasminogen activator inhibitor-1 ex-
pression in a rat model with cardiovascular remodeling induced
by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol
32:73–83, 2000
25. NAKAMURA S, NAKAMURA I, MA L, et al: Plasminogen activator
inhibitor-1 expression is regulated by the angiotensin type 1 recep-
tor in vivo. Kidney Int 58:251–259, 2000
26. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, et al: Macrophages in
renal injury. Kidney Int 45(Suppl):S79–S82, 1994
27. COOPER ME: Pathogenesis, prevention, and treatment of diabetic
nephropathy. Lancet 352:213–219, 1998
28. BAUD L, HAGEGE J, SRAER L, et al: Reactive oxygen production
by cultured rat glomerular mesangial cells during phagocytosis is
associated with stimulation of lipoxygenase activity. J Exp Med
158:1836–1842, 1983
29. YOUNG BA, JOHNSON RJ, ALPERS CE, et al: Cellular events in the
evolution of experimental diabetic nephropathy. Kidney Int 47:335–
342, 1995
30. WADA T, FURUICHI K, SAKAI N, et al: Up-regulation of monocyte
chemoattractant protein-1 in tubulointerstitial lesion of human di-
abetic nephropathy. Kidney Int 58:1492–1499, 2000
31. KELLY DJ, WILKINSON-BERKA JL, RICHARDO SD, et al: Progression
of tubulointerstitial injury by osteopontin-induced macrophage re-
cruitment in advanced diabetic nephropathy of transgenic (mRen-
2)27 rats. Nephrol Dial Transplant 17:985–991, 2002
32. VRANES D, COOPER ME, DILLEY RJ: Cellular mechanism of diabetic
vascular hypertrophy. Microvasc Res 57:8–18, 1999
33. VRANES D, DILLEY RJ, COOPER ME: Vascular changes in diabetic
kidney: Effects of ACE inhibition. J Diabetes Complication 9:296–
300, 1995
34. MAI M, GEIGER H, HILGERS KF, et al: Early interstitial changes in
hypertension-induced renal injury. Hypertension 22:754–765, 1993
35. BROWN NJ, NAKAMURA S, MA L-J, et al: Aldosterone modulates
plasminogen activator inhibitor-1 and glomerulosclerosis. Kidney
Int 58:1219–1227, 2000
36. ZHANG G, KIM H, CAI X, et al: Urokinase receptor modulatescellular
and angiogenic responses in obstructive nephropathy. J Am Soc
Nephrol 14:1234–1253, 2003
37. SHANKLAND SS, SCHOLEY JW, THAI K, et al: Expression of transform-
ing growth factor-b1 during diabetic renal hypertrophy. Kidney Int
46:430–442, 1994
38. TOBLLI JE, FERDER L, STELLA I, et al: Protective role of enalapril
for chronic tubulointerstitial lesion of hyperoxaluria. J Urology
166:275–280, 2001
39. MOGENSEN CE, CHRISTENSEN CK, VITTINGHUS F: The stages in dia-
betic renal disease. With emphasis on the stage of incipient diabetic
nephropathy. Diabetes 32(Suppl 2):64–78, 1983
40. RASCH R, DORUP J: Quantitative morphology of the rat kidney dur-
ing diabetes mellitus and insulin treatment. Diabetologia 40:802–
809, 1997
41. ZIYADEH FN, SNIPES ER, WATANABE M, et al: High glucose induces
cell hypertrophy and stimulates collagen gene transcription in prox-
imal tubule. Am J Physiol 259:F704–F714, 1990
42. GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the
remnant kidney model in the rat. J Clin Invest 98:1063–1068, 1996
43. ROCHA R, CHANDER PN, ZUCKERMAN A, et al: Role of aldosterone
in renal vascular injury in stroke-prone hypertensive rats. Hyper-
tension 33:232–237, 1999
44. PARK JB, SCHIFFRIN EL: Cardiac and vascular fibrosis and hypertro-
phy in aldosterone-infused rats: Role of endothelin-1. Am J Hyper-
tens 15:164–169, 2002
45. PU Q, NEVES F, VIRDIS A, et al: Endothelin antagonism on
aldosterone-induced oxidative stress and vascular remodelling. Hy-
pertension 42:49–55, 2003
46. ANDERSON SG, RENNKE HG, BRENNER BM: Therapeutic advantage
of converting enzyme inhibitors in arresting progressive renal dis-
ease associated with systemic hypertension in rat. J Clin Invest
77:1993–2000, 1986
47. TANAKA R, SUGIHARA K, TAKEMATSU A, et al: Internephron het-
erogeneity of growth factors and sclerosis-modulation of platelet
derived growth factor by angiotensin II. Kidney Int 47:131–139,
1995
48. KANETO H, MORRISSEY J, MCCRACKEN R, et al: Enalapril reduces
collagen type IV synthesis and expansion of the interstitium in the
obstructed rat kidney. Kidney Int 45:1637–1647, 1994
49. OIKAWA T, FREEMAN M, LO W, et al: Modulation of plasminogen
activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic
effect of renin-angiotensin inhibitors. Kidney Int 51:164–172, 1997
50. COHEN EP, FISH BL, MOULDER JE: Treatment of radiation nephropa-
thy with captopril. Radiat Res 132:346–350, 1992
51. HAMDAN AD, QUIST WC, GAGNE JB, et al: Angiotensin-converting
enzyme inhibition suppresses plasminogen activator inhibitor-1 ex-
pression in the neointima of balloon-injured rat aorta. Circulation
93:1073–1078, 1996
52. KATO S, LUYCKX VA, OTS M, et al: Renin-angiotensin blockade low-
ers MCP-1 expression in diabetic rats. Kidney Int 56:1037–1048, 1999
53. BROWN NJ, AGIRBASLI MA, WILLIAMS GH, et al: Effect of activation
and inhibition of the renin angiotensin system on plasma PAI-1 in
humans. Hypertension 32:965–971, 1998
54. BLASI ER, ROCHA R, RUDOLPH AE, et al: Aldosterone/salt induced
renal inflammation and fibrosis in hypertensive rats. Kidney Int
63:1791–1800, 2003
55. HATAKEYAMA H, MIYAMORI I, FUJITA T, et al: Vascular aldosterone.
Biosynthesis and a link to angiotensin II-induced hypertrophy of
vascular smooth muscle cells. J Biol Chem 269:24316–24320, 1994
56. SILVESTRE J-S, HEYMES C, OUBENAISSA A, et al: Activation of car-
diac aldosterone production in rat myocardial infarction. Effect of
angiotensin II receptor blockade and role in cardiac fibrosis. Circu-
lation 99:2694–2701, 1999
